Anticancer Drugs Durvalumab Oncology Pharmacology Physiotherapy

Durvalumab (Warnings-17)

In this article we will discuss Durvalumab (Warnings-17)

In this article, we will discuss Durvalumab (Warnings-17). So, let’s get started.

Hypophysitis: Durvalumab can cause immune-mediated hypophysitis. Hypophysitis can present with acute symptoms associated with mass effect such as headache, photophobia, or visual field cuts. Hypophysitis can cause hypopituitarism. Initiate symptomatic treatment including hormone replacement as clinically indicated. Withhold or permanently discontinue Durvalumab depending on severity.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.